Compare LINC & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LINC | SLBT |
|---|---|---|
| Founded | 1946 | N/A |
| Country | United States | Taiwan |
| Employees | N/A | 20 |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 813.3M | 942.1M |
| IPO Year | 2005 | 2025 |
| Metric | LINC | SLBT |
|---|---|---|
| Price | $22.29 | $1.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $45.00 | N/A |
| AVG Volume (30 Days) | ★ 694.3K | 79.0K |
| Earning Date | 05-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $261,853,000.00 | N/A |
| Revenue This Year | $15.16 | N/A |
| Revenue Next Year | $9.02 | N/A |
| P/E Ratio | $119.40 | ★ N/A |
| Revenue Growth | ★ 32.98 | N/A |
| 52 Week Low | $17.29 | $1.50 |
| 52 Week High | $56.34 | $6.25 |
| Indicator | LINC | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 23.57 | 26.81 |
| Support Level | N/A | N/A |
| Resistance Level | $25.77 | $3.36 |
| Average True Range (ATR) | 1.15 | 0.22 |
| MACD | 0.32 | -0.04 |
| Stochastic Oscillator | 9.91 | 9.21 |
Lincoln Educational Services Corp provides diversified career-oriented post-secondary education to high school graduates and working adults. The company offers programs in automotive technology, skilled trades, healthcare services, hospitality services, and business and information technology. Its reportable segments include: Campus Operations and Transitional. The majority of the revenue is generated from the Campus Operations segment, which includes all campuses that are continuing in operation and contribute to the company's core operations and performance.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.